Evolus (EOLS) Misses Q1 EPS by 21c, Misses on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Evolus Reports First Quarter 2025 Results
May 7, 2025 4:05 PM EDTGlobal Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year... More
